Medical device company Integra LifeSciences (NASDAQ:IART) will be announcing earnings results tomorrow before market hours. Here’s what to look for.
Integra LifeSciences beat analysts’ revenue expectations by 1.4% last quarter, reporting revenues of $380.8 million, flat year on year. It was a mixed quarter for the company, with a decent beat of analysts’ EPS estimates but organic revenue in line with analysts’ estimates.
Is Integra LifeSciences a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Integra LifeSciences’s revenue to grow 12.2% year on year to $445.5 million, improving from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.85 per share.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Integra LifeSciences has missed Wall Street’s revenue estimates four times over the last two years.
Looking at Integra LifeSciences’s peers in the healthcare equipment and supplies segment, some have already reported their Q4 results, giving us a hint as to what we can expect. Intuitive Surgical delivered year-on-year revenue growth of 25.2%, beating analysts’ expectations by 6.5%, and Insulet reported revenues up 17.2%, topping estimates by 2.5%. Intuitive Surgical traded down 4% following the results while Insulet was also down 1.9%.
Read our full analysis of Intuitive Surgical’s results here and Insulet’s results here.
Stocks generally had a good 2024. The Fed fought high inflation and won without sending the economy into a recession, otherwise lovingly known as a soft landing. The US Central Bank is now cutting rates. That, plus the election of Donald Trump in November 2024, sent markets even higher, and while some of the healthcare equipment and supplies stocks have shown solid performance, the group has generally underperformed, with share prices down 5.3% on average over the last month. Integra LifeSciences is down 20.7% during the same time and is heading into earnings with an average analyst price target of $26 (compared to the current share price of $20.91).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.